Usually most of the daily news is bad but today we woke up to very good news. rVSV-ZEBOV, a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus has completed phase 1 human trials in Guinea, West Africa. Vaccine efficacy was 100% Fast track this one please (Merck has 300,000 doses ready in case of an outbreak). We are highly impressed by this work and hope it will serve as a model for the future of rapid drug development and deployment in response to emerging epidemics.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32621-6/fulltext
No comments:
Post a Comment